Keytruda Combination Gives Celyad’s Off-The-Shelf CAR-T A Shot In The Arm
Allogeneics Still Waiting For Breakthrough
Celyad has been in the CAR-T field for many years, but hopes that a new focus on allogeneic platforms and new targets will put it ahead of competitors.
You may also be interested in...
The failure of the SGLT2 inhibitor is not unexpected, but allays any concerns that it could have worsened outcomes for patients with hypertension or heart disease.
The UK has announced a ‘course correction’ on its vaccination program, and looks to have maintained public confidence so far – unfortunately the same cannot be said for EU countries
The EMA and MHRA issue parallel safety updates on the vaccine, with the UK offering an alternative of the Pfizer/BioNTech or Moderna vaccines to the under 30s.